Abstracts tagged "Cardiovascular"

Abstract Number: 0284 • ACR Convergence 2021
Risk Factors for Dementia in Patients with Incident Rheumatoid Arthritis: A Population-based Cohort Study
Elena Myasoedova¹, Michelle Mielke¹, Cassondra Hulshizer¹, John Davis¹, Vijay Ramanan¹, Maria Vassilaki¹ and Cynthia Crowson², ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Eyota, MN
Background/Purpose: Growing evidence from observational studies suggests that patients with rheumatoid arthritis (RA) are at increased risk for cognitive impairment and dementia. Longitudinal population-based studies…
Abstract Number: 0679 • ACR Convergence 2021
Cardiovascular Risk Associated with Treatment of Allopurinol and Benzbromarone in Patients with Gout
Yeonghee Eun, Seonyoung Kang, Seulkee Lee, Hyungjin Kim, Jaejoon Lee, Eun-Mi Koh and Hoon-Suk Cha, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
Background/Purpose: Previous studies have shown that cardiovascular risk is increased in patients with gout. There are many studies on the effect of uric acid lowering…
Abstract Number: 1357 • ACR Convergence 2021
Clinical and Molecular Profiles Determining Cardiovascular Risk in Psoriatic Arthritis: Specific Response to Apremilast and Methotrexate
Nuria Barbarroja¹, Iván Arias de la Rosa¹, Cristobal Román-Rodriguez², Ignacio Gomez-Garcia³, Clementina López Medina⁴, M.Lourdes Ladehesa-Pineda⁵, Carlos Pérez-Sánchez⁶, Maria del Carmen Ábalos-Aguilera², Alejandra Patiño-Trives⁷, Isabel Añón-Oñate⁸, Maria Jose Pérez-Galán⁸, Rocio Guzmán-Ruiz², Maria del Mar Malagón², Chary Lopez-Pedrera², alejandro Escudero², Eduardo Collantes-Estevez² and Maria Dolores López-Montilla², ¹University of Cordoba/IMIBIC/Reina Sofia Hospital, Cordoba, Spain, ²IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, ³Rheumatology Department, Reina Sofia University Hospital. Cordoba (Spain) / University of Cordoba (Spain) / Maimonides Institute for Biomedical Research (IMIBIC). Cordoba (Spain) / Physical Medicine and Rehabilitation Department. Infanta Margarita Hospital. Cabra (Spain), Córdoba, Spain, ⁴Department of Rheumatology, Reina Sofia Hospital, IMIBIC, University of Cordoba, Cordoba, Spain/ Department of Rheumatology, University of Paris, Cochin Hospital, Paris, France, ⁵Hospital Universitario Reina Sofía, Córdoba, Spain, ⁶IMIBIC, Córdoba, Spain, ⁷Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, ⁸Rheumatology department, University Hospital of Jaen, Jaen, Spain
Background/Purpose: 1) to evaluate clinical and subclinical markers of cardiovascular (CV) disease risk and its relationship with inflammation, disease activity and metabolic comorbidities in PsA…
Abstract Number: 1939 • ACR Convergence 2021
Risk of Cardiovascular Outcomes in Patients Treated with Tofacitinib: First Results from the Safety of TofAcitinib in Routine Care Patients with Rheumatoid Arthritis (STAR-RA) Study
Farzin Khosrow-Khavar, Seoyoung Kim, Hemin Lee, Su Been Lee and Rishi Desai, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Recent reports from a post-marketing safety trial, “ORAL Surveillance”, indicated an increased risk of cardiovascular (CV) outcomes in RA patients treated with tofacitinib. Thus,…
Abstract Number: 0045 • ACR Convergence 2021
Endothelial Cells from Patients with DMARD Naïve, Active Inflammatory Arthritis Demonstrate Pro-inflammatory Sensitisation That Is Reversed by Therapy Initiation
Robert Maughan¹, Marie Lang¹, Anton Olsson¹, Andrew Porter¹, Antonia Greeves², Taryn Youngstein³, Charis Pericleous¹ and Justin Mason¹, ¹Imperial College London, London, United Kingdom, ²Hammersmith Hospital, London, United Kingdom, ³Hammersmith Hospital & Imperial College London, London, United Kingdom
Background/Purpose: Inflammatory arthritides (IA) including rheumatoid arthritis are associated with increased cardiovascular disease (CVD) mortality. Although inflammation-driven endothelial dysfunction is considered a major factor, the…
Abstract Number: 0285 • ACR Convergence 2021
Risk of Cardiovascular Disease in Newly Diagnosed Rheumatoid Arthritis: A Current Risk Assessment
Reinder Raadsen¹, Romy Hansildaar¹, Maaike Heslinga², Arno van Kuijk¹ and Michael Nurmohamed³, ¹Reade, Amsterdam, Netherlands, ²Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands, ³Reade and Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands
Background/Purpose: Patients with rheumatoid arthritis (RA) are known to have an increased risk of developing, mainly ischemic cardiovascular diseases (CVD). This is partly explained by…
Abstract Number: 0708 • ACR Convergence 2021
Cardiovascular Risk in Myositis Patients Compared to General Population – Preliminary Data from a Single-centre Cross-sectional Study
Sabina Oreska¹, Hana Storkanova¹, Maja Spiritovic², Barbora Hermankova³, Petr Cesak⁴, Jaroslav Kudlicka⁵, Vladimir Tuka⁶, Ondrej Mikes⁵, Martin Satny⁵, Eva Chytilova⁵, Zdislava Krupickova⁵, Michal Vrablik⁵, Karel Pavelka¹, Ladislav Senolt¹, Herman Mann¹, Jiri Vencovsky⁷ and Michal Tomcik¹, ¹Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ²Institute of Rheumatology, Department of Physiotherapy, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, ³Department of Physiotherapy, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, ⁴Department of Human Movement Laboratory, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁵3rd Department of Internal Medicine, General University Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁶3rd Department of Internal Medicine, General University Hospital and 1st Faculty of Medicine, Charle, Prague, Czech Republic, ⁷Institute of Rheumatology, Prague, Czech Republic
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are associated with systemic inflammation, limited mobility, and glucocorticoid treatment, which can have a negative impact on metabolic disease, atherogenesis,…
Abstract Number: 1427 • ACR Convergence 2021
Reduction of Cardiovascular Disease and Mortality versus Risk of New Onset Diabetes with Statin Use in Patients with Rheumatoid Arthritis
Gulsen Ozen¹, Sophie Dell’Aniello², Sofia Pedro³, Kaleb Michaud⁴ and Samy Suissa⁵, ¹University of Nebraska Medical Center, Bellevue, NE, ²Center for Clinical Epidemiology, Lady Davis Research Institute - Jewish General Hospital, Montréal, QC, Canada, ³Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Center for Clinical Epidemiology, Lady Davis Research Institute - Jewish General Hospital;Depts of Epidemiology and Biostatistics and of Medicine, McGill University, Montréal, QC, Canada
Background/Purpose: The risks of death and of type 2 diabetes mellitus (T2DM) are increased in RA mainly due to inflammation mediated accelerated cardiovascular disease (CVD)…
Abstract Number: 1941 • ACR Convergence 2021
The Risk of Venous Thromboembolic Events in Patients with RA Aged ≥ 50 Years with ≥ 1 Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors
Christina Charles-Schoeman¹, Roy Fleischmann², Eduardo Mysler³, Maria Greenwald⁴, Cunshan Wang⁵, All-shine Chen⁵, Carol A Connell⁵, John C Woolcott⁶, Sujatha Menon⁵, Yan Chen⁷, Kristen Lee⁷ and Zoltan Szekanecz⁸, ¹Department of Medicine, University of California, Los Angeles, Los Angeles, CA, ²Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ³Organización Médica de Investigación, Buenos Aires, Argentina, ⁴Desert Medical Advances, Palm Desert, CA, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Inc, New York, NY, ⁸Division of Rheumatology, University of Debrecen, Faculty of Medicine, Debrecen, Hungary
Background/Purpose: ORAL Surveillance (NCT02092467) was a randomized, open-label, non-inferiority, Phase 3b/4 study that assessed the relative risk of major adverse cardiovascular (CV) events (MACE) and…
Abstract Number: 0076 • ACR Convergence 2021
Predicting the Transitions Between Lupus Anticoagulant Status and Thrombosis in SLE Using a Multi-state Markov Model
Selcan Demir¹, Jessica Li², Laurence Magder³ and Michelle Petri⁴, ¹Hacettepe University Faculty of Medicine, Ankara, Turkey, ²Johns Hopkins University, Baltimore, MD, ³University of Maryland, Baltimore, Baltimore, MD, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Antiphospholipid syndrome (APS) is a significant cause of morbidity and mortality in patients with SLE and lupus anticoagulant (LAC) positivity is the best predictor…
Abstract Number: 0286 • ACR Convergence 2021
Cardiovascular Disease Risk in Inflammatory Arthritis Patients Still Substantially Elevated in 2020
Reinder Raadsen¹, Femke Hooijberg¹, Laura Boekel¹, Erik Vogelzang², Gertjan Wolbink¹, Willem Lems³, Arno van Kuijk¹ and Michael Nurmohamed⁴, ¹Reade, Amsterdam, Netherlands, ²Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands, ³VUmc, Amsterdam, Netherlands, ⁴Reade and Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands
Background/Purpose: Patients with inflammatory rheumatic diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) are at a higher risk for developing…
Abstract Number: 0831 • ACR Convergence 2021
Safety and Efficacy of Tofacitinib vs TNF Inhibitors in RA Patients Aged 50 Years or Older with One or More Cardiovascular Risks: Results from a Phase 3b/4 Randomized Safety Trial
Steven R Ytterberg¹, Deepak L Bhatt², Ted Mikuls³, Gary G Koch⁴, Jose L Rivas⁵, Rebecca Germino⁶, Sujatha Menon⁶, Yanhui Sun⁷, Cunshan Wang⁶, Andrea B Shapiro⁸, Keith S Kanik⁶, Carol A Connell⁶ and Roy Fleischmann⁹, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ³University of Nebraska Medical Center, Omaha, NE, ⁴Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁵Pfizer SLU, Madrid, Spain, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer CRDC, Shanghai, China (People's Republic), ⁸Pfizer Inc, Peapack, NJ, ⁹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: ORAL Surveillance (NCT02092467) was mandated by the US Food and Drug Administration to assess the relative risk of tofacitinib vs TNF inhibitors (TNFi), based…
Abstract Number: 1428 • ACR Convergence 2021
Association Between Ongoing Glucocorticoid Use and Major Adverse Cardiovascular Events Among Veterans with Rheumatoid Arthritis
Beth Wallace¹, Yuqing Gao², Punyasha Roul³, Shirley Cohen-Mekelberg², Bryant England³, Ted Mikuls³, Daniel Clauw⁴, Wyndy Wiitala², Rodney Hayward⁵, Jeremy Sussman⁶ and Akbar Waljee⁵, ¹Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ²VA Ann Arbor Healthcare System, Center for Clinical Management Research, Ann Arbor, MI, ³University of Nebraska Medical Center, Omaha, NE, ⁴University of Michigan, Ann Arbor, MI, ⁵University of Michigan, VA Ann Arbor Healthcare System, Center for Clinical Management Research, Ann Arbor, MI, ⁶University of Michigan; VA Ann Arbor Healthcare System; Center for Clinical Management Research, Ann Arbor, MI
Background/Purpose: A third of RA patients use long-term glucocorticoids (GCs) despite a known dose-dependent association with major adverse cardiovascular (CV) events (MACE). Prior work suggests…
Abstract Number: 0128 • ACR Convergence 2021
Increased Risk of Major Adverse Cardiac Events in Patients with Systemic Lupus Erythematosus After Non-Cardiac Surgery
Sebastian Bruera¹, Xiudong Lei², Brandon Blau¹, Hui Zhao², Anita Deswal², Jinoos Yazdany³, Sharon Giordano² and Maria Suarez-Almazor², ¹Baylor College of Medicine, Houston, TX, ²University of Texas MD Anderson Cancer Center, Houston, TX, ³University of California San Francisco, San Francisco, CA
Background/Purpose: The association between systemic lupus erythematosus (SLE) and cardiovascular disease has been well-studied. Cardiovascular disease is a risk factor for major adverse cardiac events…
Abstract Number: 0287 • ACR Convergence 2021
20 Years Follow-up of Cardiovascular Event Risk in Rheumatoid Arthritis Compared to Diabetes
Reinder Raadsen¹, Rabia Agca², Alexandre Voskuyl³, Maarten Boers⁴, Willem Lems⁵, Arno van Kuijk¹ and Michael Nurmohamed², ¹Reade, Amsterdam, Netherlands, ²Reade and Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands, ³Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands, ⁴Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, ⁵VUmc, Amsterdam, Netherlands
Background/Purpose: Patients with rheumatoid arthritis have an increased risk for developing cardiovascular diseases (CVD) compared to the general population, similar to the CVD risk in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].